Clinical trial / 2019
Non-animal chondroitin sulfate improved knee function, pain scores, and inflammatory markers in overweight adults with knee osteoarthritis.
A randomized, double-blind, placebo-controlled pilot study evaluated 60 overweight adults with symptomatic knee osteoarthritis assigned to 600 mg of non-animal chondroitin sulfate (CS) daily or placebo for 12 weeks. The experimental group showed a significant increase in Tegner Lysholm Knee Scoring (+10.64 points; 95% CI 5.57, 15.70; p < 0.01) and a decrease in WOMAC score (-12.24 points; 95% CI -16.01, -8.38; p < 0.01). Significant decreases were also seen in C-reactive protein (-0.14 mg/dL; 95% CI -0.26, -0.04; p < 0.01), erythrocyte sedimentation rate (-5.01 mm/h; 95% CI -9.18, -0.84; p < 0.01), and visual analogue scale pain scores in both knees.
- Study type
- Randomized, double-blind, placebo-controlled pilot study
- Who was studied
- 60 overweight adults with symptomatic knee osteoarthritis
- What was measured
- Knee pain, quality of life, inflammation markers (CRP, ESR), and body composition
THE PAPER
Effectiveness of Non-Animal Chondroitin Sulfate Supplementation in the Treatment of Moderate Knee Osteoarthritis in a Group of Overweight Subjects: A Randomized, Double-Blind, Placebo-Controlled Pilot Study.
Rondanelli M, Braschi V, Gasparri C, Nichetti M, Faliva MA, Peroni G, Naso M, Iannello G, Spadaccini D, Miraglia N, Putignano P, Alalwan TA, Perna S. Nutrients, 2019.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.